Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-498-0020
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.59 million
Profitability
Miscellaneous
Employees86
Next Earnings Date8/13/2019 (Estimated)
OptionableNot Optionable
Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions
What is Mersana Therapeutics' stock symbol?
Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."
How were Mersana Therapeutics' earnings last quarter?
Mersana Therapeutics Inc (NASDAQ:MRSN) released its quarterly earnings results on Thursday, May, 9th. The company reported $0.70 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.03) by $0.73. The business had revenue of $41.04 million for the quarter, compared to analysts' expectations of $30.11 million. Mersana Therapeutics had a negative net margin of 61.68% and a negative return on equity of 57.49%. View Mersana Therapeutics' Earnings History.
When is Mersana Therapeutics' next earnings date?
What price target have analysts set for MRSN?
6 Wall Street analysts have issued 12 month price objectives for Mersana Therapeutics' shares. Their predictions range from $12.00 to $16.00. On average, they anticipate Mersana Therapeutics' share price to reach $14.00 in the next year. This suggests a possible upside of 265.5% from the stock's current price. View Analyst Price Targets for Mersana Therapeutics.
What is the consensus analysts' recommendation for Mersana Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mersana Therapeutics.
Has Mersana Therapeutics been receiving favorable news coverage?
Media stories about MRSN stock have been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mersana Therapeutics earned a news sentiment score of 2.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Mersana Therapeutics.
Who are some of Mersana Therapeutics' key competitors?
Some companies that are related to Mersana Therapeutics include Wave Life Sciences (WVE), Arvinas (ARVN), Emisphere Technologies (EMIS), Y-mAbs Therapeutics (YMAB), CannTrust (CNTTF), Eagle Pharmaceuticals (EGRX), Kiniksa Pharmaceuticals (KNSA), Propanc Biopharma (PPCB), Endo International (ENDP), Stoke Therapeutics (STOK), Rhythm Pharmaceuticals (RYTM), Kura Oncology (KURA), Omeros (OMER), DiaMedica Therapeutics (DMCAF) and Advanz Pharma (CXRXF).
What other stocks do shareholders of Mersana Therapeutics own?
Who are Mersana Therapeutics' key executives?
Mersana Therapeutics' management team includes the folowing people:
- Ms. Anna Protopapas, Pres, CEO & Director (Age 55)
- Mr. David A. Spellman, Chief Financial Officer (Age 42)
- Dr. Timothy B. Lowinger, Sr. VP & Chief Scientific Officer (Age 55)
- Mr. Mikhail Papisov Ph.D., Co-Founder
- Ms. Sarah Carmody, Exec. Director of Investor Relations & Corp. Communications
When did Mersana Therapeutics IPO?
(MRSN) raised $75 million in an IPO on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
How do I buy shares of Mersana Therapeutics?
Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mersana Therapeutics' stock price today?
One share of MRSN stock can currently be purchased for approximately $3.83.
How big of a company is Mersana Therapeutics?
Mersana Therapeutics has a market capitalization of $182.76 million and generates $10.59 million in revenue each year. The company earns $-64,260,000.00 in net income (profit) each year or ($2.79) on an earnings per share basis. Mersana Therapeutics employs 86 workers across the globe.View Additional Information About Mersana Therapeutics.
What is Mersana Therapeutics' official website?
How can I contact Mersana Therapeutics?
Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]
MarketBeat Community Rating for Mersana Therapeutics (NASDAQ MRSN)
MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote "Outperform" if you believe MRSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRSN will underperform the S&P 500 over the long term. You may vote once every thirty days.
